UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-40215 Instil Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 83-2072195 (State or other jurisdic ...

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update With the clearance of the U.S. IND, initiation of the U.S. clinical trial of AXN-2510/IMM2510 ("'2510") anticipated before the end of 2025 Updated '2510 monotherapy data in squamous-NSCLC to be presented at IASLC's 2025 World Conference on Lung Cancer (WCLC) by ImmuneOnco DALLAS, TX, August 13, 2025 (GLOBE NEWSWIRE) Instil Bio, Inc. ("Instil") (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing ...

Core Insights - Instil Bio, Inc. has received FDA clearance for the Investigational New Drug (IND) application for AXN-2510, a bispecific antibody targeting PD-L1 and VEGF, aimed at treating multiple solid tumors [1][3] - The company plans to initiate a phase 1 trial of AXN-2510 as a monotherapy for patients with relapsed/refractory solid tumors before the end of 2025 [2] - Initial safety and efficacy results from a phase 2 trial of AXN-2510 in combination with chemotherapy for first-line non-small cell lung cancer (NSCLC) in China are expected to be shared in the second half of 2025 [1][2] Company Overview - Instil Bio is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies [3] - The lead asset, AXN-2510, is positioned as a differentiated treatment option for various solid tumors [3]

Group 1: Momentum Investing Overview - Momentum investing involves following a stock's recent trend, with the aim of buying high and selling higher, capitalizing on established price movements [1] - The Zacks Momentum Style Score helps investors identify effective metrics for assessing momentum in stocks [2] Group 2: Instil Bio, Inc. (TIL) Performance - Instil Bio, Inc. currently holds a Momentum Style Score of A and a Zacks Rank of 2 (Buy) [3][4] - TIL shares have increased by 4.07% over the past week, while the Zacks Medical - Biomedical and Genetics industry has decreased by 2.9% [6] - Over the past quarter, TIL shares have risen by 47.62%, and by 188.4% over the last year, significantly outperforming the S&P 500's gains of 5.72% and 10.37% respectively [7] Group 3: Trading Volume and Earnings Outlook - TIL's average 20-day trading volume is 429,110 shares, indicating a bullish sign with rising stock prices [8] - In the past two months, one earnings estimate for TIL has increased, raising the consensus estimate from -$8.30 to -$7.71 [10] - For the next fiscal year, one estimate has moved upwards with no downward revisions, indicating positive earnings outlook [10] Group 4: Conclusion - Considering the positive momentum indicators and earnings outlook, TIL is positioned as a promising stock for near-term gains [12]

Core Viewpoint - Instil Bio, Inc. (TIL) has shown significant stock price appreciation of 134% over the past four weeks, with analysts projecting a mean price target of $118.67, indicating a potential upside of 246.7% from the current price of $34.23 [1] Price Targets and Analyst Consensus - The average price target for TIL ranges from a low of $51 to a high of $180, with a standard deviation of $64.73, suggesting variability in analyst estimates [2] - The lowest estimate indicates a 49% increase, while the highest suggests a 425.9% upside, highlighting the potential for significant price movement [2] - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price direction, which can serve as a starting point for further research [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about TIL's earnings prospects, as evidenced by a positive trend in earnings estimate revisions, which correlates with potential stock price increases [11] - Over the past 30 days, one earnings estimate has increased, leading to a 7.2% rise in the Zacks Consensus Estimate for the current year [12] - TIL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13]

Core Insights - Instil Bio, Inc. has appointed John Maraganore, Ph.D., to the Board of Directors of its subsidiary Axion Bio, Inc., which is focused on developing AXN-2510, a PD-L1xVEGF bispecific antibody targeting solid tumors, particularly non-small cell lung cancer (NSCLC) [1][2] - The appointment is aimed at enhancing leadership to maximize the value of the AXN-2510 program for both patients and shareholders, with expectations of redefining the standard of care for solid tumors [2] - AXN-2510 is currently in a Phase 2 trial in combination with chemotherapy for first-line NSCLC, with early signs of safety and efficacy being reported [2] Company Overview - Instil Bio is a clinical-stage biopharmaceutical company dedicated to developing novel therapies, with AXN-2510 as its lead asset [3] - Axion Bio, a wholly-owned subsidiary of Instil Bio, is specifically focused on the development of AXN-2510 for multiple solid tumors [4] Leadership Background - Dr. John Maraganore brings over 30 years of biotechnology experience, having previously served as the founding CEO of Alnylam Pharmaceuticals, where he led the company to a market capitalization exceeding $40 billion [2] - His expertise spans drug discovery, clinical development, and strategic partnerships, making him a valuable asset for guiding the advancement of next-generation cancer therapies [2]

Group 1: Momentum Investing Overview - Momentum investing involves following a stock's recent trend, with the aim of buying high and selling higher, capitalizing on established price movements [1] - The Zacks Momentum Style Score helps investors identify effective metrics for assessing momentum in stocks [2] Group 2: Instil Bio, Inc. (TIL) Performance - Instil Bio, Inc. currently holds a Momentum Style Score of A and a Zacks Rank of 2 (Buy), indicating strong potential for outperformance [3][4] - Over the past week, TIL shares have increased by 28.21%, significantly outperforming the Zacks Medical - Biomedical and Genetics industry, which rose by only 0.25% [6] - In a longer timeframe, TIL shares have gained 72.33% over the past quarter and 180.49% over the last year, while the S&P 500 has only moved 2.37% and 14.4%, respectively [7] Group 3: Trading Volume and Earnings Outlook - TIL's average 20-day trading volume is 383,563 shares, which is a bullish indicator when combined with rising stock prices [8] - Recent earnings estimate revisions for TIL show one upward revision for the full year, increasing the consensus estimate from -$8.30 to -$7.71 over the past 60 days [10] - For the next fiscal year, there has been one upward revision with no downward changes, indicating a positive earnings outlook [10] Group 4: Conclusion - Considering all performance metrics and earnings outlook, TIL is positioned as a strong buy candidate with a Momentum Score of A, making it a noteworthy option for investors seeking short-term gains [12]

Core Insights - Instil Bio, Inc. has appointed Dr. Jamie Freedman as Chief Medical Officer, bringing extensive experience in oncology drug development and a successful track record in leading programs through all phases of development, regulatory approval, and commercialization [1][2]. Company Overview - Instil Bio is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel cancer therapies, with its lead asset being AXN-2510, a PD-L1xVEGF bispecific antibody aimed at treating multiple solid tumor cancers [3]. Leadership and Expertise - Dr. Freedman has over 20 years of leadership experience in biopharma drug development, having held executive roles at major pharmaceutical companies such as Genentech, AstraZeneca, GSK, and Merck, leading to 15 drug approvals and successful launches across various therapeutic areas [2]. - He is also committed to health equity, having pioneered inclusive trials for underserved populations in the US and Africa, and continues to treat patients with blood and solid tumor cancers [2]. Product Development - AXN-2510 is positioned to potentially redefine the standard of care for solid tumors, with Dr. Freedman expressing excitement about the opportunity to accelerate its development with scientific rigor and clinical urgency [2].

Company Overview - Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies [2] - The company's lead asset, AXN-2510, is a novel and differentiated PD-L1xVEGF bispecific antibody aimed at treating multiple solid tumors [2] Upcoming Events - Bronson Crouch, the Chief Executive Officer of Instil Bio, will present at the Jefferies Global Healthcare Conference on June 5, 2025, at 4:20 PM ET [1] - A live webcast of the presentation will be available through a specified weblink [1]

Core Viewpoint - Instil Bio, Inc. (TIL) has received an upgrade to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, indicating a positive outlook for the company's stock price [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors often rely on earnings estimates to determine the fair value of a company's shares, leading to significant price movements based on their buying or selling actions [4]. Recent Performance and Projections - Instil Bio is projected to earn -$7.71 per share for the fiscal year ending December 2025, reflecting a year-over-year change of 32.3% [8]. - Over the past three months, the Zacks Consensus Estimate for Instil Bio has increased by 32.8%, indicating a positive trend in earnings estimates [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7]. - The upgrade of Instil Bio to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].